Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy

To evaluate spot-scanning proton arc therapy (SPArc) and multi-field robust optimized intensity modulated proton therapy (RO-IMPT) in treating stage III non-small-cell lung cancer (NSCLC) patients.

Source: Radiation Oncology - February 27, 2018 Category: Cancer & Oncology Authors: Xiaoqiang Li, Peyman Kabolizadeh, Di Yan, An Qin, Jun Zhou, Ye Hong, Thomas Guerrero, Inga Grills, Craig Stevens and Xuanfeng Ding Tags: Research Source Type: research